Skip to main content

Table 3 PFS and survival results (ITT population)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

 

ITT population n = 70

Median progression free survival, months

14.58 [95% CI; 10.97-18.75]

Progression free survival rate at 12 months, %

58.6 [95% CI; 47.0-70.1]

Median overall survival, months

17.08 [95% CI; 13.56-29.57]

Survival rate at 6 months, %

88.6 [95% CI; 81.1-96.0]

Survival rate at 12 months, %

68.6 [95% CI; 57.7-79.4]

Survival rate at 18 months, %

43.4 [95% CI; 31.3-55.6]

Survival rate at 24 months, %

>37*

  1. *95% CI was not estimated (data were not mature).